{"id":14392,"date":"2021-05-03T12:38:50","date_gmt":"2021-05-03T12:38:50","guid":{"rendered":"https:\/\/clinlabint.com\/?p=14392"},"modified":"2021-05-03T12:38:50","modified_gmt":"2021-05-03T12:38:50","slug":"cn-bio-introduces-the-physiomimix-ooc-multi-organ-microphysiological-system","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/cn-bio-introduces-the-physiomimix-ooc-multi-organ-microphysiological-system\/","title":{"rendered":"CN Bio introduces the PhysioMimix OOC multi-organ microphysiological system"},"content":{"rendered":"
\"PhysioMimix

CN Bio’s PhysioMimix OOC multi-organ microphysiological system.<\/p><\/div>\n

CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), has launched its new PhysioMimix\u2122 OOC Multi-Organ MPS. The next-generation platform combines CN Bio\u2019s\u00a0in vitro\u00a0<\/em>3D liver model, whose phenotype and functions mimic that\u00a0in vivo,\u00a0<\/em>with a\u00a0range of other organs\u00a0to more accurately recapitulate the multi-organ and systemic effects observed in humans.<\/p>\n

Demonstrating a key milestone in the Company\u2019s mission to develop the most complete human \u2018body-on-a-chip\u2019 in the laboratory, the PhysioMimix OOC Multi-Organ MPS will provide advanced insights into the potential effects of novel therapeutics that were previously only achievable using animal models.<\/p>\n

CN Bio\u2019s Multi-Organ MPS enables researchers to generate sophisticated\u00a0in vitro<\/em>\u00a0models that better represent human inter-organ crosstalk effects compared to single-organ MPS, or animal models. This system can be used to decrease the risk of clinical trial failures due to cross-species translational differences and can be used in the development of new human-specific modalities for which animal models are unsuited.<\/p>\n

The Company\u2019s advanced 3D liver model can be reliably and easily interconnected with other organs (such as gut, lung or kidney) to provide a human\u00a0in vitro<\/em>\u00a0alternative to animal or\u00a0in silico<\/em>\u00a0first pass metabolism studies (ADME), to elicit a deeper human-specific mechanistic understanding of disease states and to identify reactive metabolite-driven toxicity or multi-organ toxicity. Furthermore,\u00a0in vitro<\/em>\u00a0to\u00a0in vivo<\/em>\u00a0clinical predictions can be extrapolated using Physiologically-Based Pharmacokinetics (PBPK) mathematical models, to increase the accuracy and precision of data translation. For existing PhysioMimix users, an upgrade path is available.<\/p>\n

Prior to launch, the system has undergone extensive internal and external validation by the University of Pittsburgh, and by a major pharmaceutical company.<\/p>\n

Inherent biological differences<\/h4>\n

“The inherent biological differences of animal models with human physiology frequently result in the misrepresentation of pharmacological processes, contributing to the large proportion of new medicines that fail in clinical trials. Furthermore, in certain scenarios, animal models are unsuitable for efficacy and safety evaluation due to their genetic and immunological differences,” said Dr David Hughes, CEO, CN Bio.
\n<\/em><\/p>\n

\u201cOur new multi-organ platform addresses the needs of a wider customer base, whilst providing the same ease-of-use, robustness, and reliability as the single-organ system which has been on the market since 2018. This launch extends CN Bio\u2019s reach from world-leading provider of single-organ-on-a-chip technologies into multi-organ-on-a-chip, as we strive to expand the boundaries of humanized pre-clinical research and development.\u201d<\/p>\n

Professor Alan Wells, Professor of Pathology, Integrative Systems Biology Department, University of Pittsburgh, said:\u00a0\u201cThe pathobiology of disease, even if limited to one organ, does not occur in isolation to the rest of the body. To understand how other events affect the pathology in question requires their constant communication. We are finding these networks key to tumour progression in metastatic sites, to address the Achilles heel of cancer therapy.\u201d<\/p>\n